Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme
- PMID: 20532954
- DOI: 10.1007/s11060-010-0245-2
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme
Abstract
We have previously shown that expanded/activated γδ T cells from healthy donors are cytotoxic to GBM cell lines and primary GBM explants. In this report, we examined the therapeutic effect of intracranial infusion of expanded/activated γδ T cells on human minimal and established U251 tumor xenografts in athymic nude mice. Immunohistochemistry was used to determine the presence of NKG2D ligands on cell lines and tumors, and blocking studies were used to determine the effect of these ligands on γδ T cell recognition. Expanded/activated γδ T cells were prepared by 18-day culture in RPMI, human serum (HS), anti-CD2, IL-12, IFN-γ, and OKT-3. Anti-GBM activity of the cell product was assessed using in vitro cytotoxicity assays against the GBM cell line U251MG in suspension and in adherent culture. Ex vivo expanded/activated γδ T cells were of the effector/memory phenotype, expressed Th1 cytokines, and effectively killed U251 cells in vitro. Xenografts were prepared using a U251 cell line following transfection with a firefly luciferase gene to monitor tumor progression. Mice treated with γδ T cells showed slower progression of both new and established GBM xenografts versus mice that received vehicle only as determined by photon emission over time. Median survival was improved in all γδ T cell treated groups between 32 and 50 days by Kaplan-Meier analysis. U251 cells expressed ULBP-2 and ULBP-3, although blocking of these reduced in vitro cytotoxicity of γδ T cells to U251MG by only 33 and 25%, respectively. These studies show that expanded/activated γδ T cells can mediate killing of new or established GBM xenografts, reduce tumor progression, and constitute a potentially effective novel immunotherapeutic strategy against GBM.
Similar articles
-
CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.PLoS One. 2013 Aug 7;8(8):e68729. doi: 10.1371/journal.pone.0068729. eCollection 2013. PLoS One. 2013. PMID: 23950874 Free PMC article.
-
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.PLoS One. 2013;8(1):e51805. doi: 10.1371/journal.pone.0051805. Epub 2013 Jan 11. PLoS One. 2013. PMID: 23326319 Free PMC article.
-
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.Neuro Oncol. 2009 Aug;11(4):357-67. doi: 10.1215/15228517-2008-111. Epub 2009 Feb 11. Neuro Oncol. 2009. PMID: 19211933 Free PMC article.
-
Gammadelta T cells as immune effectors against high-grade gliomas.Immunol Res. 2009;45(1):85-95. doi: 10.1007/s12026-009-8114-9. Immunol Res. 2009. PMID: 19711198 Review.
-
γδ T cells as a potential therapeutic agent for glioblastoma.Front Immunol. 2023 Oct 20;14:1273986. doi: 10.3389/fimmu.2023.1273986. eCollection 2023. Front Immunol. 2023. PMID: 37928546 Free PMC article. Review.
Cited by
-
The Role of γδ T-Lymphocytes in Glioblastoma: Current Trends and Future Directions.Cancers (Basel). 2023 Dec 10;15(24):5784. doi: 10.3390/cancers15245784. Cancers (Basel). 2023. PMID: 38136330 Free PMC article. Review.
-
Analysis of tumor-infiltrating gamma delta T cells in rectal cancer.World J Gastroenterol. 2016 Apr 7;22(13):3573-80. doi: 10.3748/wjg.v22.i13.3573. World J Gastroenterol. 2016. PMID: 27053849 Free PMC article.
-
Immunotherapy of brain cancers: the past, the present, and future directions.Clin Dev Immunol. 2010;2010:296453. doi: 10.1155/2010/296453. Epub 2011 Mar 8. Clin Dev Immunol. 2010. PMID: 21437175 Free PMC article. Review.
-
Cellular immunotherapy for malignant gliomas.Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Expert Opin Biol Ther. 2016. PMID: 27434205 Free PMC article. Review.
-
Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.Front Immunol. 2024 Feb 7;15:1299044. doi: 10.3389/fimmu.2024.1299044. eCollection 2024. Front Immunol. 2024. PMID: 38384458 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources